

# Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

Daniela Manno, Philip Ayieko, David Ishola, Muhammed O. Afolabi, Baimba Rogers, Frank Baiden, Alimamy Serry-Bangura, Osman M. Bah, Brian Köhn, Ibrahim Swaray, Kwabena Owusu-Kyei, Godfrey T. Otieno, Dickens Kowuor, Daniel Tindanbil, Elizabeth Smout, Cynthia Robinson, Babajide Keshinro, Julie Foster, Katherine Gallagher, Brett Lowe, Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones

We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014–2016 Ebola outbreak in Sierra Leone, 8% were seropositive for virus antibodies but never experienced disease symptoms. Antibody concentration increased with age.

**E**bola virus (EBOV) antibodies have been found in populations that have never experienced documented Ebola outbreaks and in persons who reported no history of Ebola virus disease (EVD) (1). The clinical significance of these findings is unknown. We conducted a cross-sectional study in healthy adults and children from a population affected by the 2014–2016 EVD outbreak in Sierra Leone and explored the association of antibody seropositivity and concentration with potential risk factors for EBOV infection.

Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (D. Manno, P. Ayieko, D. Ishola, M.O. Afolabi, F. Baiden, B. Köhn, K. Owusu-Kyei, G.T. Otieno, D. Kowuor, D. Tindanbil, E. Smout, J. Foster, K. Gallagher, B. Lowe, B. Greenwood, D. Watson-Jones); Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania (P. Ayieko, D. Watson-Jones); University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Sierra Leone (B. Rogers, A. Serry-Bangura, O.M. Bah, I. Swaray, B. Leigh); Janssen Vaccines and Prevention, Leiden, the Netherlands (C. Robinson, B. Keshinro, M. Douoguih)

DOI: <https://doi.org/10.3201/eid2803.211496>


## The Study

We conducted a seroprevalence study in Kambia District, Sierra Leone, during March 2016–June 2018. We nested the study within the screening visit of the EBO-VAC-Salone (<https://www.ebovac.org>) randomized controlled trial (RCT), which evaluated the safety and immunogenicity of the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (ClinicalTrials.gov, no. NCT02509494) (2,3). Persons who reported having a previous EVD diagnosis and persons who previously received a candidate Ebola vaccine were ineligible for the RCT, and we excluded them from the seroprevalence study. We recruited adults first, then recruited children in 3 age cohorts: 12–17, 4–11, and 1–3 years of age.

We measured IgG to EBOV glycoprotein (GP) by using the Filovirus Animal Non-Clinical Group (FANG) ELISA (Q2 Solutions Vaccine Testing Laboratory, <https://www.q2labsolutions.com>). We determined seropositivity by using a cutoff of >607 ELISA units (EU)/mL, which was calculated previously in an EBOV-naïve population in West Africa (4) (Appendix, <https://wwwnc.cdc.gov/EID/article/28/3/21-1496-App1.pdf>).

Among 1,282 study participants (Figure), 687 (53.6%) were <18 years of age (median 16 years, IQR 7–25 years), and 827 (64.5%) were male. Among 1,272 participants with antibody results, we considered 107 (8.4%, 95% CI 7.0%–10.0%) seropositive for EBOV GP IgG by using the prespecified cutoff.

Risk factor analysis showed that, after adjusting for age and sex, the only characteristic associated with seropositivity was living in a household compound with ≥1 pigs during the outbreak (adjusted odds ratio [OR] 4.5, 95% CI 1.6–13.0;  $p = 0.01$ ) (Tables 1, 2; Appendix



**Figure.** Flow chart of participants screened for the Ebola virus vaccine trial and seroprevalence study in a community affected by the 2014–2016 Ebola outbreak, Sierra Leone.

Table 1). The EBOV antibody geometric mean concentration (GMC) was higher in participants  $\geq 5$  years of age than in younger children (Appendix Table 1). After adjusting for age and sex, only pig ownership remained associated with antibody concentration (adjusted GMC ratio 3.0, 95% CI 1.5–5.9;  $p < 0.01$ ) (Table 2).

The 8.4% seroprevalence in our study is within the range of estimates (0%–24%) from prior studies; however, this range is large because of the use of different assays, different seroprevalence thresholds, different levels of exposure to EVD cases, and studies undertaken in different geographic areas and at different timepoints relative to reported outbreaks (1). Our estimate is similar to the baseline EBOV antibody seroprevalence (4.0%) measured in another Ebola vaccine trial conducted in Liberia during the 2014–2016 EVD outbreak that used the same assay and cutoff (5).

Similar to results from previous studies, our findings showed a statistically significant increase in EBOV antibody concentration with participants' age, possibly because of increased exposure of older age groups to EBOV or to other infections that could induce cross-reactive antibodies to the EBOV GP (6,7). Potential exposures to EVD, such as healthcare work, contact with EVD cases, and funeral attendance, which were associated with EBOV transmission in other studies (8), were not associated with EBOV antibody seropositivity or concentration in our study. However, few participants reporting those risk fac-

tors, and our study might have lacked the power to detect such associations.

We found an independent association of both EBOV antibody seropositivity and concentration with residence in a household compound that owned  $\geq 1$  pigs during the Ebola outbreak. Pigs can be experimentally infected with EBOV and can transmit the virus to nonhuman primates (9). EBOV-specific antibodies have been found in pigs in Sierra Leone and Guinea, suggesting that pigs can be naturally infected by EBOV (10,11). Pigs in the Philippines have been found to be naturally infected with Reston virus, an EBOV strain that is not known to cause disease in humans. Reston virus-specific antibodies were found in healthy farmers in contact with the infected pigs, suggesting potential transmission from pigs to humans (12). However, we found no association of EBOV antibody with having other domestic animals, in particular dogs, which also could be infected with EBOV (13,14).

One strength of our study is that we conducted our study in an area with prolonged EBOV transmission during the 2014–2016 EVD outbreak. Further, we explored a wide range of potential risk factors for EBOV acquisition, and we used the FANG ELISA, which has been proven to be more precise and accurate than a commercial alternative (4).

The first limitation of our study is that the parent RCT did not require random sampling of potential participants' households, which could have affected the generalizability of our results to the

general population. The RCT recruitment was age-staggered, and the youngest age cohort (1–3 years of age) was recruited >2 years after the EVD outbreak ended. However, a sensitivity analysis suggested that year of recruitment had a negligible confounding effect on the lower EBOV antibody concentrations observed in the youngest children (Appendix Table 2). Our study was conducted at the end of the 2014–2016 EVD outbreak in Sierra Leone, when public health measures to contain EBOV transmission had been in place for several months and the

population had received messages about EVD prevention. This factor could have caused an underreporting of behaviors considered to put persons at risk for EVD. For example, hunting and consumption of bushmeat was rarely reported by our participants, in contrast with some reports that describe frequent hunting and bushmeat consumption in West Africa (15). The association of both antibody seropositivity and concentration with pig ownership is based on only 18 participants who reported keeping  $\geq 1$  pigs in their household compound at the time of the

**Table 1.** Potential EVD exposure in community or work during the 2014–2016 EVD outbreak and antibody seropositivity and GMC among participants in a study of EBOV GP-specific binding antibody seropositivity, Sierra Leone\*

Risk factors	No. (%), n = 1,282	No. seropositive/ no. tested (%)	OR (95% CI)	Adjusted OR (95% CI)†	GMC, EU/mL (95% CI)	GMC ratio (95% CI)	Adjusted GMC ratio (95% CI)‡
Living in a village or town with Ebola cases, n = 1,281							
N	199 (15.5)	10/198 (5.1)	Referent, p = 0.049	Referent, p = 0.125	49 (40–58)	Referent, p = 0.010	Referent, p = 0.882
Y	1,082 (84.5)	97/1,073 (9.0)	1.9 (1.0–3.6)	1.7 (0.8–3.3)	65 (60–71)	1.3 (1.1–1.6)	1.0 (0.8–1.3)
Knowing someone who had Ebola							
No, don't know	1,044 (81.4)	82/1,036 (7.9)	Referent, p = 0.193		61, 56–67)	Referent, p = 0.204	
Y	238 (18.6)	25/236 (10.6)	1.4 (0.9–2.2)		70 (57–85)	1.1 (0.92–1.4)	
No. EVD cases known by participant							
0	1,044 (81.4)	82/1,036 (7.9)	Referent, p = 0.55		61 (56–67)	Referent, p = 0.382	
1	125 (9.8)	13/125 (10.4)	1.4 (0.7–2.5)		64 (49–85)	1.1 (0.8–1.4)	
2–3	66 (5.2)	8/65 (12.3)	1.6 (0.8–3.5)		84 (57–124)	1.4 (0.9–2.0)	
>3	47 (3.7)	4/46 (8.7)	1.1 (0.4–3.2)		66 (44–99)	1.1 (0.7–1.6)	
Closest relationship with an EVD case, n = 1,280							
No relationship‡	1,044 (81.5)	82/1,036 (7.9)	Referent, p = 0.197		61, 56–67)	Referent, p = 0.259	
Close family§	27 (2.1)	1/27 (3.7)	0.5 (0.1–3.3)		52 (33–81)	0.9 (0.5–1.3)	
Other relative	52 (4.1)	6/51 (11.8)	1.6 (0.6–3.7)		64 (42–96)	1.0 (0.7–1.6)	
Friend	59 (4.6)	4/59 (6.8)	0.8 (0.3–2.4)		64 (45–91)	1.1 (0.7–1.5)	
Community member	98 (7.7)	14/97 (14.4)	2.0 (1.1–3.7)		86 (62–120)	1.4 (1.0–2.0)	
Living in the same household with an EVD case, n = 1,280							
N	1,269 (99.1)	107/1,260 (8.5)	–		63 (58–68)	Referent, p = 0.814	
Y	11 (0.9)	0/10 (0.0)	–		56 (31–102)	0.9 (0.5–1.6)	
Caring for an EVD case, n = 1,281							
N	1,272 (99.3)	107/1,262 (8.5)	–		63 (58–68)	Referent, p = 0.600	
Y	9 (0.7)	0/9 (0.0)	–		48 (24–98)	0.8 (0.4–1.6)	
Direct body contact with an EVD case, n = 1,281							
N	1,275 (99.5)	107/1,265 (8.5)	–		62 (57–67)	Referent, p = 0.640	
Y	6 (0.5)	0/6 (0.0)	–		83 (28–242)	1.3 (0.5–3.9)	
Attending a funeral of an EVD case							
N	1,263 (98.5)	105/1,254 (8.4)	Referent, p = 0.691		62 (57–67)	Referent, p = 0.346	
Y	19 (1.5)	2/18 (11.1)	1.4 (0.3–6.0)		87 (37–204)	1.4 (0.6–3.3)	
Healthcare frontline worker during EVD outbreak							
No, NA¶	1,254 (97.8)	105/1,244 (8.4)	Referent, p = 0.802		63 (58–69)	Referent, p = 0.798	
Y	28 (2.2)	2/28 (7.1)	0.8 (0.2–3.6)		58 (36–93)	0.9 (0.6–1.5)	

\*Seropositivity defined as >607 EU/mL. EBOV GP-specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. EBOV GP, Ebola virus glycoprotein; EU, ELISA units; EVD, Ebola virus disease; GMC, geometric mean concentration; NA, not applicable; OR, odds ratio.

†Adjusted for age and sex.

‡Participant did not know anyone with Ebola.

§Participant was the parent or child or spouse or sibling of an EVD case.

¶Not applicable because participant was a child or did not have a job.

**Table 2.** Potential risk factors for transmission of Ebola virus from animals during the 2014–2016 EVD outbreak and antibody seropositivity and GMC among participants in a study of EBOV GP–specific binding antibody seropositivity, Sierra Leone\*

Risk factors	No. (%), n = 1,282	No. seropositive/ no. tested (%)	OR (95% CI)	Adjusted OR (95% CI)†	GMC, EU/mL (95% CI)	GMC ratio (95% CI)	Adjusted GMC ratio (95% CI)‡
Number of domestic animals in the participant's compound							
0	503 (39.2)	45/498 (9.0)	Referent, p = 0.558		59 (51–67)	Referent, p = 0.462	
1–5	374 (29.2)	33/371 (8.9)	1.0 (0.6–1.6)		65 (55–75)	1.1 (0.9–1.3)	
>5	405 (31.6)	29/403 (7.2)	0.8 (0.5–1.3)		66 (57–76)	1.1 (0.9–1.3)	
Having the following domestic animals in the compound‡							
Dog							
N	1,116 (87.1)	90/1,107 (8.1)	Referent, p = 0.349		66 (52–84)	Referent, p = 0.559	
Y	165 (12.9)	17/164 (10.4)	1.3 (0.8–2.3)		62 (57–67)	1.1 (0.8–1.4)	
Cat							
N	951 (74.2)	80/943 (8.5)	Referent, p = 0.887		61 (56–67)	Referent, p = 0.400	
Y	330 (25.8)	27/328 (8.2)	1.0 (0.6–1.5)		66 (56–78)	1.1 (0.9–1.3)	
Goat, sheep							
N	870 (67.9)	76/863 (8.8)	Referent, p = 0.465		62 (56–68)	Referent, p = 0.781	
Y	411 (32.1)	31/408 (7.6)	0.9 (0.6–1.3)		62 (57–67)	1.0 (0.9–1.2)	
Pig							
N	1,263 (98.6)	102/1,253 (8.1)	Referent, p = 0.015	Referent, p = 0.014	61 (57–67)	Referent, p < 0.001	Referent, p = 0.001
Y	18 (1.4)	5/18 (27.8)	4.3 (1.5–12.4)	4.5 (1.6–13.0)	200 (93–431)	3.3 (1.5–7.1)	3.0 (1.5–5.9)
Other							
N	825 (64.4)	73/817 (8.9)	Referent, p = 0.370		61 (55–68)	Referent, p = 0.513	
Y	456 (35.6)	34/454 (7.5)	0.8 (0.5–1.3)		65 (57–74)	1.1 (0.9–1.3)	
Touching sick or dead domestic animals							
N	1,253 (97.7)	106/1,243 (8.5)	Referent, p = 0.275		63 (58–68)	Referent, p = 0.824	
Y	29 (2.3)	1/29 (3.5)	0.4 (0.1–2.8)		59 (36–97)	0.9 (0.6–1.6)	
Hunting for wild animals§							
N	1,261 (99.3)	105/1,251 (8.4)	Referent, p = 0.779		63 (58–68)	Referent, p = 0.859	
Y	9 (0.7)	1/9 (11.1)	1.4 (0.2–11.0)		57 (17–191)	0.9 (0.3–3.1)	
Touching sick or dead wild animals							
N	1,277 (99.6)	106/1,267 (8.4)	Referent, p = 0.419		62 (58–68)	Referent, p = 0.825	
Y	5 (0.4)	1/5 (20.0)	2.7 (0.3–24.7)		54 (8–369)	0.9 (0.1–5.9)	
Consuming bushmeat							
N	1,275 (99.4)	106/1,265 (8.4)	Referent, p = 0.606		62 (58–68)	Referent, p = 0.962	
Y	7 (0.6)	1/7 (14.3)	1.8 (0.2–15.3)		61 (14–274)	1.0 (0.2–4.4)	

\*Seropositivity defined as >607 EU/mL. EBOV GP–specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. EBOV, Ebola virus; EU, ELISA units; GMC, geometric mean concentration; GP, glycoprotein; OR, odds ratio.

†Adjusted for age and sex.

‡Participants could indicate >1 type of domestic animal.

§Types of wild animals hunted by participants who answered yes included monkeys, duiker antelopes, bats, and rodents.

outbreak. This association could have occurred by chance, although the evidence of an association is quite strong. The observed association also could be confounded by unrecorded risk factors among participants who also kept pigs, such as EBOV transmission clustering in participants from a household that also owned pigs. However, that possibility seems unlikely because none of the seropositive participants who owned pigs reported contact with an EVD case, and these participants all came from different households. Finally, we are not able to determine whether EBOV antibody seropositivity in this setting reflects true asymptomatic infection because

we cannot exclude underreporting of earlier EVD symptoms and we have not yet investigated cross-reactivity with other viral infections. Whether EBOV seropositivity reflects acquired immunity that might provide some protection against future EBOV infections also is unclear.

Our findings suggest that the role of pigs as potential, occasional reservoirs of EBOV needs to be investigated further. The presence of antibodies binding the EBOV GP could also suggest circulation of other infectious agents, probably viruses, inducing cross-reactivity with the EBOV GP, but this possibility needs further investigation.

## Conclusions

The incidence of EBOV infection during the 2014–2016 EVD outbreak in Sierra Leone could have been higher than previously reported; 8.4% of adults and children from a community affected by the outbreak who never experienced symptoms of EVD had serologic responses to EBOV above a cutoff threshold. Our study suggests that EBOV might cause asymptomatic infection, but whether underreporting of symptoms, FANG assay specificity, or exposure to other viral infections that could generate cross-reactive antibodies also contributed to the results is unclear. These questions would benefit from further investigation to help define the extent of future EVD outbreaks. Countries at high risk for EVD outbreaks should be aware of the risk of asymptomatic or paucisymptomatic infections.

## Acknowledgments

We thank Christian Hansen for support in the sample size calculation for the study protocol and Kathy Baisley for advice on the statistical analysis. We thank Viki Bockstal and Kerstin Luhn for advice on the interpretation of FANG ELISA results. We thank the site study team, including study physicians and other clinicians; the data management team; the quality assurance, social science, community engagement teams, the laboratory team, the College of Medicine and Allied Health Sciences (COMAHS) and the London School of Hygiene & Tropical Medicine (LSHTM) project management and administrative teams; and colleagues from World Vision, GOAL, and the Ebola Vaccine Deployment, Acceptance and Compliance (EBODAC) project. We thank all the study participants and their families. We also thank the other EBOVAC 1 Consortium partners, the University of Oxford, and Institut National de la Santé et de la Recherche Médicale (INSERM) in France for their support for this study.

This study was funded by the Innovative Medicines Initiative 2 Joint Undertaking (grant no. 115854, EBOVAC 1 project).

## About the Author

Dr. Manno is a clinical epidemiologist and assistant professor at the London School of Hygiene and Tropical Medicine. Her primary research interests include epidemiological studies and clinical trials in infectious diseases.

## References

1. Bower H, Glynn JR. A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. *Sci Data*. 2017;4:160133. <https://doi.org/10.1038/sdata.2016.133>
2. Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. *Lancet Infect Dis*. 2022;22:97–109. [https://doi.org/10.1016/S1473-3099\(21\)00125-0](https://doi.org/10.1016/S1473-3099(21)00125-0)
3. Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. *Lancet Infect Dis*. 2022;22:110–22. [https://doi.org/10.1016/S1473-3099\(21\)00128-6](https://doi.org/10.1016/S1473-3099(21)00128-6)
4. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, et al. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. *J Virol Methods*. 2018;255:84–90. <https://doi.org/10.1016/j.jviromet.2018.02.018>
5. Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, et al.; PREVAIL I Study Group. Phase 2 placebo-controlled trial of two vaccines to prevent ebola in Liberia. *N Engl J Med*. 2017;377:1438–47. <https://doi.org/10.1056/NEJMoa1614067>
6. Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A, et al. High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo. *BMC Infect Dis*. 2016;16:263. <https://doi.org/10.1186/s12879-016-1607-y>
7. Bouree P, Bergmann JF. Ebola virus infection in man: a serological and epidemiological survey in the Cameroons. *Am J Trop Med Hyg*. 1983;32:1465–6. <https://doi.org/10.4269/ajtmh.1983.32.1465>
8. Brainard J, Hooper L, Pond K, Edmunds K, Hunter PR. Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. *Int J Epidemiol*. 2016;45:102–16. <https://doi.org/10.1093/ije/dyv307>
9. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. *Sci Rep*. 2012;2:811. <https://doi.org/10.1038/srep00811>
10. Fischer K, Jabaty J, Suluku R, Strecker T, Groseth A, Fehling SK, et al. Serological evidence for the circulation of ebolaviruses in pigs from Sierra Leone. *J Infect Dis*. 2018;218(suppl\_5):S305–11. PubMed <https://www.doi.org/10.1093/infdis/jiy330>
11. Fischer K, Camara A, Troupin C, Fehling SK, Strecker T, Groschup MH, et al. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea. *Transbound Emerg Dis*. 2020;67:724–32. <https://doi.org/10.1111/tbed.13391>
12. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, et al. Discovery of swine as a host for the Reston ebolavirus. *Science*. 2009;325:204–6. <https://doi.org/10.1126/science.1172705>
13. Haun BK, Kamara V, Dweh AS, Garalde-Machida K, Forkay SSE, Takaaze M, et al. Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report. *PLoS Negl Trop Dis*. 2019;13(7):e0007614. PubMed <https://doi.org/10.1371/journal.pntd.0007614>
14. Fischer K, Suluku R, Fehling SK, Jabaty J, Koroma B, Strecker T, et al. Ebola virus neutralizing antibodies in dogs from Sierra Leone, 2017. *Emerg Infect Dis*. 2020;26:760–3. <https://doi.org/10.3201/eid2604.190802>
15. Luiselli L, Hema E, Segniabeto G, Ouattara V, Eniang EA, Parfait G, et al. Bushmeat consumption in large urban centres in West Africa. *Oryx*. 2020;54:731–4.

Address for Correspondence: Daniela Manno, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; email: daniela.manno@lshtm.ac.uk

# Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

## Appendix

### Methods

#### Study Design

We conducted a cross-sectional seroprevalence study of immunoglobulin G (IgG) antibodies against Ebola virus (EBOV) glycoprotein (GP) during March 16, 2016–June 29, 2018. We nested the study within the screening visit of the EBOVAC-Salone (<https://www.ebovac.org>) randomized controlled trial (RCT), which was being conducted to evaluate the safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines (protocol no. VAC52150EBL3001; ClinicalTrials.gov no. NCT02509494).

#### Study Participants

We enrolled participants from 3 sites in Kambia District, northern Sierra Leone; 2 sites in Kambia town and 1 site in the neighboring community of Rokupr, a rural village ≈15 km from Kambia town. Both areas were affected by widespread and prolonged EBOV transmission during the Ebola virus disease (EVD) epidemic in West Africa (*1*).

We recruited adults first, during March 16, 2016–December 29, 2016; then we enrolled children during March 21 2017–June 29, 2018 in 3 age cohorts: 12–17, 4–11, and 1–3 years of age. We counselled potential participants on the importance of providing accurate medical information, including any history of EVD, close contact with a person who had EVD, or prior vaccination with a candidate Ebola vaccine. Persons who reported having an EVD diagnosis in the past or who previously had been vaccinated with a candidate Ebola vaccine were considered ineligible for both the RCT and we did not include them in the seroprevalence study.

We obtained informed consent from adult participants and from parents or guardians for participants who were <18 years of age. We also asked children  $\geq 7$  years of age to give their assent for participation. Ethical approval for the study was received from the Sierra Leone Ethics Committee and the London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee (reference no. 10537).

### **Study Procedures**

We interviewed study participants to collect information on potential risk factors for EBOV infection, including residence in areas where EVD cases occurred during the 2014–2016 outbreak, healthcare work during the outbreak, travel, contact with EVD cases, funeral attendance, and contact with or consumption of wild animals. Because EBOV also is known to infect domestic animals, including dogs and pigs, we also collected information on contacts with these animals during the outbreak (2–7).

Approximately 2 mL of blood was collected at enrollment. Samples were left to clot for 30 minutes, then centrifuged at 1,500 g (rpm) for 10 min at the study clinics. At the research laboratory, we aliquoted serum and froze it at  $-20^{\circ}\text{C}$ . We stored serum samples at  $-20^{\circ}\text{C}$  until shipped in controlled temperature containers to the laboratory in the United States for sample analysis. Q2 Solutions Vaccine Testing Laboratory (<https://www.q2labsolutions.com>) measured IgG against EBOV GP by using the EBOV GP Filovirus Animal Non-Clinical Group (FANG) ELISA. Validation of the FANG ELISA was endorsed by the US Food and Drug Administration (FDA) in February 2017 (Q2 Solutions, pers. comm., 2017. FANG ELISA has a lower limit of quantification (LLOQ), 36.11 ELISA units (EU)/mL, and has no established cutoff to distinguish seropositive persons after EBOV infection from seronegative persons (Q2 Solutions, pers. comm., 2019). To determine seropositivity, we used a cutoff of  $>607$  EU/mL, which was calculated in a previous study using serum samples collected from 100 EBOV-naive persons from Mali during 2004–2011 and was defined as the antibody titer of 3 SD above the mean ( $\log_{10}$  transformed) (8). This cutoff was considered appropriate to provide an estimate of the prevalence of IgG to EBOV GP in a setting in West Africa. We also conducted a post-hoc analysis with an alternative cutoff calculated by using serum samples from 388 EBOV-naive persons from the United Kingdom (See Alternative cutoff calculation).

## **Sample Size and Statistical Analysis**

We did not conduct a formal sample size calculation for this study because the number of enrolled participants was determined by the number of participants screened for the RCT. We also had limited data on the estimated prevalence of IgG to EBOV GP in the general population after an EVD outbreak. However, we estimated that a sample of 1,250 persons would enable us to estimate a prevalence of 1.0% with a precision of approximately  $\pm 0.55\%$  (i.e., 95% CI 0.45%–1.55%).

We conducted our statistical analysis for all participants with an available FANG ELISA result. We calculated the seroprevalence of IgG to EBOV GP as a percentage of study participants who had an antibody concentration above the prespecified cutoff of  $>607$  EU/mL. We obtained the antibody geometric mean concentration (GMC) and 95% CI by calculating the mean and 95% CI of the log-transformed values, and then transforming these results back into the original units by taking the antilogs. To calculate GMC, we imputed values below the LLOQ as LLOQ/2 (18.055 EU/mL). We calculated the odds ratio (OR) and 95% CI to measure the association between potential risk factors for acquisition of EBOV and seropositivity, using logistic regression. We calculated the GMC ratio and 95% CI to measure the association between the same risk factors and IgG antibody concentration, using linear regression. For the risk factor analysis, we selected a total of 26 variables out of 47 questions related to risk factors or potential confounders obtained from participants' interviews. Among those questions, we used 11 questions about household characteristics (ownership of goods, such as television, radio, etc.) to calculate the socioeconomic status of the household with principal component analysis. We adjusted the multivariable analyses for age and sex (a priori confounding factors). We conducted a post-hoc sensitivity analysis adjusting for year of enrollment to explore whether the age distribution of the EBOV GP antibody concentration could have been influenced by the age-staggered recruitment procedure. We used Stata 16 (StataCorp LLC, <https://www.stata.com>) for all the statistical analyses.

## **Alternative Cutoff Calculation**

In a post-hoc analysis, we calculated an alternative seropositivity cutoff by using baseline Ebolavirus IgG levels from 388 healthy persons from the United Kingdom who were enrolled in an Ebola vaccine trial (protocol no. VAC52150EBL2001) during 2014–2015 (9). The investigators of this study conducted the sample analysis by using the FANG ELISA at Q2



Solutions Vaccine Testing Laboratory. Among the 388 participants, 26 had a baseline result above the LLOQ of 36.11 EU/mL. We imputed values below the LLOQ as LLOQ/2 (18.055 EU/mL). We defined the seropositivity cutoff as the antilog value of 3 SD above the mean of the  $\log_{10}$  transformed values, as calculated in a previous study (8).

The EBOV GP antibody GMC in the 388 EBOV-naive persons from the UK was 20.44 EU/mL, with a geometric standard deviation (GSD) of 1.69 EU/mL. To calculate seropositivity cutoff we use the formula:  $GMC \times (GSD)^3$ .

$$\text{Seropositivity cutoff} = 20.44 \times (1.69)^3 = 99.03 \text{ EU/mL}$$

## Results

### Detailed Description of Study Results

A total of 1,524 potential participants were screened for the VAC52150EBL3001 trial, of whom 1,315 (86.3%) agreed to participate in the seroprevalence study (Figure). Blood samples were available for 1,282 (97.5%) participants, 687 (53.6%) of whom were aged <18 years (median age 16 years, IQR = 7–25 years) and 827 (64.5%) of whom were male (Appendix Table 1).

Only 238 (18.6%) participants reported that they knew someone who had EVD during the outbreak (Table 1). Eleven (0.9%) participants reported that someone in their household had experienced EVD and 9 (0.7%) participants cared for someone with EVD. Six (0.5%) participants had direct body contact with an EVD patient. Only 28 participants (2.2%) undertook healthcare or frontline (i.e., burial team) work during the EVD outbreak. Only 9 (0.7%) reported hunting for wild animals and only 7 (0.6%) said that they had consumed bushmeat (Table 2).

Because the FANG ELISA results were indeterminate in 10 of the 1,282 samples, the estimation of IgG seroprevalence and GMC were based on results from 1,272 participants. Of those 1,272 samples, 684 (53.8%) had a result that was above the LLOQ of 36.11 EU/mL for the FANG ELISA. Overall, 107 participants (8.4%, 95% CI 7.0%–10.0%) had a result above the prespecified seropositivity cutoff of 607 EU/mL and we considered these samples to be seropositive for EBOV GP in our study.

There were fewer seropositive participants among children <5 years compared with older age groups (Appendix Table 1). However, we found no statistical evidence of an association between seropositivity and age. We also saw no statistically significant difference in the percentage of seropositive samples by sex. In univariable analyses, we noted some evidence of an association between seropositivity and living in a village or town with EVD cases (Table 1), or in a household compound with  $\geq 1$  pigs at the time of the outbreak (Table 2). After adjusting for age and sex, only having  $\geq 1$  pigs in the household compound at the time of the outbreak remained associated with EBOV seropositivity (adjusted OR 4.5, 95% CI 1.6–13.0,  $p = 0.01$ ) (Table 2). A post-hoc analysis with an alternative cutoff calculated by using serum samples from 388 EBOV-naive persons from the United Kingdom, showed similar results (see Alternative Cutoff Analysis results).

We noted a statistically significant increase in EBOV GP binding antibody GMC with age and GMC was higher in participants  $\geq 5$  years of age than in younger children (Appendix Table 1). This association remained after adjusting for year of recruitment, which suggested that it was not due to the age-staggered recruitment process (Appendix Table 2). Male persons had a slightly higher GMC than female persons but we saw no evidence of a difference after adjusting for age. Other statistically significant variables associated with EBOV GP binding antibody concentration on univariable analysis were education, frequency of travel outside the place of residence, living in a village or town with EVD cases, and having  $\geq 1$  pigs in the household compound at the time of the outbreak (Table 1, Table 2; Appendix Table 1). After adjusting for age and sex, we saw no evidence of an association between antibody concentration and education or travel or residence in a village or town with EVD cases. However, we still saw evidence of an association between antibody concentration and the presence of  $\geq 1$  pigs in the household compound at the time of the outbreak (adjusted GMC ratio 3.0, 95% CI 1.5%–5.9%,  $p < 0.01$ ) (Table 2).

### **Alternative Cutoff Analysis Results**

Because the assay has no established diagnostic serostatus threshold, we calculated a range of seropositivity estimates by using different cut-off values and the prespecified cutoff used in our study (Appendix Table 3). We also conducted a post-hoc analysis with an alternative cutoff calculated by using serum samples from EBOV-naive persons from the United Kingdom (see Alternative Cutoff Calculation). Overall, 411 participants (32.3%, 95% CI 29.7%–34.9%)

had a result above the seropositivity cutoff of 99.03 EU/mL and we considered these samples to be seropositive for EBOV GP in our supplementary analysis.

The number of seropositive participants increased with age and fewer children <5 years of age were seropositive compared with persons in older age groups (Appendix Table 4). We saw no statistically significant difference in the percentage of seropositive participants by sex. In univariable analyses, we noted some evidence of an association between seropositivity and education and living in a household compound that kept  $\geq 1$  pigs at the time of the outbreak (Appendix Tables 4–6). After adjusting for age and sex, only having  $\geq 1$  pigs in the household compound at the time of the outbreak remained associated with EBOV seropositivity (adjusted OR 4.1, 95% CI 1.5–11.4,  $p < 0.01$ ) (Appendix Table 6).

## **Discussion**

### **FANG ELISA Uses and Limitations**

The FANG ELISA used in our study has been proven to be more precise and accurate than a commercial alternative for the assessment of immune response after Ebola vaccination (8). Despite being the best option available at the time, the assay has some limitations. Positivity has been observed in samples from countries that have never experienced EBOV outbreaks, which indicates that the assay might not have a high specificity (10–13). For this reason, we adopted a seropositivity cutoff that has been calculated in EBOV-naïve persons from West Africa, although this analysis was not done in the same laboratory where our study samples were analyzed (8). Another limitation of the FANG ELISA is that it only detects IgG against the EBOV GP, but a concomitant test to detect IgG against the EBOV nucleoprotein could have enabled a better identification of previous EBOV infections, as noted in another study (14). A seropositive cutoff of  $>607$  EU/mL could be considered high for a seroepidemiologic study, considering that in some Ebola vaccine trials the antibody concentration that was achieved post vaccination was sometimes below this threshold, even in participants considered as vaccine responders (10–13). However, we believe that this cutoff is suitable to provide a conservative estimate of the prevalence of IgG to EBOV GP in West Africa but it would not be appropriate to use this cutoff for the interpretation of post-vaccination results in a clinical trial. Most Ebola vaccine trials that used the FANG ELISA for the measurement of postvaccination antibody response have adopted

a vaccine responder definition that was based on an x-fold increase over prevaccination baseline values, instead of using a predefined cutoff (10–13). We are aware that, without an established diagnostic serostatus threshold, the choice of a cutoff can be arbitrary. Thus, we also analyzed the data as a continuous variable, i.e., EBOV IgG concentration and we conducted a post-hoc analysis using an alternative cutoff calculated in EBOV-naive persons from the United Kingdom and these analyses showed similar results.

## References

1. World Health Organization. Ebola maps from 30 March 2016: Geographical distribution of new and total confirmed cases [cited 2021 Mar 1].  
[http://apps.who.int/ebola/sites/default/files/thumbnails/image/sitrep\\_casecount\\_40.png?ua=1](http://apps.who.int/ebola/sites/default/files/thumbnails/image/sitrep_casecount_40.png?ua=1)
2. Allela L, Bourry O, Pouillot R, Délicat A, Yaba P, Kumulungui B, et al. Ebola virus antibody prevalence in dogs and human risk. *Emerg Infect Dis*. 2005;11:385–90.
3. Haun BK, Kamara V, Dweh AS, Garalde-Machida K, Forkay SSE, Takaaze M, et al. Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report. *PLoS Negl Trop Dis*. 2019;13(7):e0007614.
4. Gumusova S, Sunbul M, Leblebicioglu H. Ebola virus disease and the veterinary perspective. *Ann Clin Microbiol Antimicrob*. 2015;14:30.
5. Fischer K, Camara A, Troupin C, Fehling SK, Strecker T, Groschup MH, et al. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea. *Transbound Emerg Dis*. 2020;67:724–32.
6. Fischer K, Jabaty J, Suluku R, Strecker T, Groseth A, Fehling SK, et al. Serological evidence for the circulation of ebolaviruses in pigs from Sierra Leone. *J Infect Dis*. 2018;218:S305–11.
7. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. *Sci Rep*. 2012;2:811.
8. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, et al. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. *J Virol Methods*. 2018;255:84–90.
9. Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, et al.; EBOVAC2 EBL2001 Study Group. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis*. 2021;21:493–506.

10. Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. *J Infect Dis.* 2019;220:57–67.
11. Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. *J Infect Dis.* 2019;220:46–56.
12. Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. *Lancet Infect Dis.* 2022;22:110–22.
13. Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. *Lancet Infect Dis.* 2022;22:97–109.
14. Richardson E, Kelly J, Barrie M, Mesman A, Karku S, Quiwa K, et al. Minimally symptomatic infection in an Ebola 'hotspot': a cross-sectional serosurvey. *PLoS Negl Trop Dis.* 2016;10(11):e0005087.

**Appendix Table 1.** Sociodemographic characteristics, Ebola virus glycoprotein-specific binding antibody seropositivity, and geometric mean concentration among participants in a study of EBOV GP-specific binding antibody seropositivity, Sierra Leone\*

Characteristics	No. (%) n = 1,282	No. seropositive/no. tested (%)	OR (95% CI)	Adjusted OR (95% CI)†	GMC, EU/mL (95% CI)	GMC ratio (95% CI)	Adjusted GMC ratio (95% CI)‡
Age group, y							
1–4	243 (19.0)	14/240 (5.8)	Referent, 1.0 (p = 0.184)	Referent, 1.0 (p = 0.165)‡	32 (26–38)	Referent, 1.0 (p<0.001)	Referent, 1.0 (p<0.001)‡
5–9	170 (13.3)	18/168 (10.7)	1.9 (0.9–4.0)	1.9 (0.9–4.0)	69 (54–88)	2.2 (1.6–2.9)	2.2 (1.6–2.9)
10–19	354 (27.6)	24/353 (6.8)	1.2 (0.6–2.3)	1.2 (0.6–2.3)	71 (61–82)	2.2 (1.8–2.8)	2.2 (1.8–2.8)
20–39	390 (30.4)	39/387 (10.1)	1.8 (1.0–3.4)	1.9 (1.0–3.6)	77 (66–90)	2.4 (1.9–3.0)	2.3 (1.9–2.9)
≥40	125 (9.7)	12/124 (9.7)	1.7 (0.8–3.9)	1.8 (0.8–3.9)	72 (56–92)	2.3 (1.7–3.1)	2.2 (1.7–3.0)
Sex							
F	455 (35.5)	39/451 (8.7)	Referent, 1.0 (p = 0.823)	Referent, 1.0 (p = 0.560)‡	54 (48–62)	Referent, 1.0 (p = 0.018)	Referent, 1.0 (p = 0.125)‡
M	827 (64.5)	68/821 (8.3)	1.0 (0.6–1.4)	0.9 (0.6–1.3)	67 (61–74)	1.2 (1.0–1.5)	1.1 (1.0–1.4)
Highest education level							
No education	362 (28.2)	25/360 (6.9)	Referent, 1.0 (p = 0.572)		42 (37–49)	Referent, 1.0 (p<0.001)	Referent, 1.0 (p = 0.653)
Primary, grades 1–6	378 (29.5)	35/374 (9.4)	1.4 (0.8–2.4)		74 (63–86)	1.7 (1.4–2.2)	1.1 (0.8–1.5)
Secondary school	480 (37.4)	43/477 (9.0)	1.3 (0.8–2.2)		72 (63–82)	1.7 (1.4–2.1)	1.0 (0.7–1.3)
College, university	62 (4.9)	4/61 (6.6)	0.9 (0.3–2.8)		73 (54–100)	1.7 (1.2–2.4)	0.9 (0.6–1.5)
Household socioeconomic status							
Low	470 (36.7)	36/464 (7.8)	Referent, 1.0 (p = 0.805)		57 (50–66)	Referent, 1.0 (p = 0.294)	
Middle	396 (30.9)	34/394 (8.6)	1.1 (0.7–1.8)		66 (57–76)	1.1 (0.9–1.4)	
High	416 (32.5)	37/414 (8.9)	1.2 (0.7–1.9)		66 (57–75)	1.1 (0.9–1.4)	
Number of persons (adults and children) in the household, n = 1,276							
<5	274 (21.5)	21/270 (7.8)	Referent, 1.0 (p = 0.769)		59 (49–70)	Referent, 1.0 (p = 0.300)	
5–9	529 (41.4)	48/527 (9.1)	1.2 (0.7–2.0)		68 (59–77)	1.2 (0.9–1.4)	
≥10	473 (37.1)	38/469 (8.1)	1.0 (0.6–1.8)		60 (53–68)	1.0 (0.8–1.3)	
Number of children in the household, n = 1,274							
0–2	466 (36.6)	41/463 (8.9)	Referent, 1.0 (p = 0.646)		64 (56–73)	Referent, 1.0 (p = 0.854)	
3–5	536 (42.1)	40/530 (7.6)	0.8 (0.5–1.3)		61 (54–69)	1.0 (0.8–1.1)	
>5	272 (21.3)	25/271 (9.2)	1.0 (0.6–1.8)		64 (54–75)	1.0 (0.8–1.2)	
Frequency of travel outside of village or town of residence, n = 1,276							
Never traveled	510 (40.0)	33/507 (6.5)	Referent, 1.0 (p = 0.186)		55 (49–63)	Referent, 1.0 (p = 0.042)	Referent, 1.0 (p = 0.578)
Every day	19 (1.5)	2/19 (10.5)	1.7 (0.4–7.6)		110 (59–204)	2.0 (1.0–3.7)	1.5 (0.8–3.0)
≥1×/wk	58 (4.5)	9/58 (15.5)	2.6 (1.2–5.8)		90 (57–142)	1.6 (1.0–2.6)	1.3 (0.8–1.9)
≥1×/mo.	235 (18.4)	21/232 (9.1)	1.4 (0.8–2.5)		68 (56–82)	1.2 (1.0–1.5)	1.0 (0.8–1.3)
<1×/mo.	454 (35.6)	41/450 (9.1)	1.4 (0.9–2.3)		63 (55–72)	1.1 (0.9–1.4)	1.0 (0.8–1.3)

\*Seropositivity defined as >607 EU/mL. p values calculated by using likelihood ratio test. EBOV–GP, Ebola virus glycoprotein; EVD, Ebola virus disease; GMC, geometric mean concentration; OR, odds ratio. EBOV, Ebola virus; EU, ELISA units;.

†Adjusted for age and sex.

‡Age adjusted for sex. Sex adjusted for age.

**Appendix Table 2.** Association between antibody concentration and age at recruitment, before and after adjusting for year of recruitment, among participants in a study of EBOV GP-specific binding antibody seropositivity, Sierra Leone\*

Characteristics	No. (%), n = 1,282	GMC, EU/mL (95% CI)	GMC ratio (95% CI)	Adjusted GMC ratio (95% CI)
Age group, y				
1–4	243 (19.0)	32 (26–38)	Referent, 1.0 (p<0.001)	Referent, 1.0 (p<0.001)†
5–9	170 (13.3)	69 (54–88)	2.2 (1.6–2.9)	2.1 (1.5–2.9)
10–19	354 (27.6)	71 (61–82)	2.2 (1.8–2.8)	2.1 (1.5–2.9)
20–39	390 (30.4)	77 (66–90)	2.4 (1.9–3.0)	2.2 (1.4–3.5)
≥40	125 (9.7)	72 (56–92)	2.3 (1.7–3.1)	2.1 (1.3–3.4)
Year of recruitment				
2016	595 (46.4)	75 (67–85)	Referent, 1.0 (p<0.001)	Referent, 1.0 (p = 0.856)‡
2017	401 (31.3)	68 (58–78)	0.9 (0.7–1.1)	1.0 (0.7–1.4)
2018	286 (22.3)	38 (32–44)	0.5 (0.4–0.6)	0.9 (0.6–1.4)

\*p values calculated by using likelihood ratio test. EU, ELISA units; GMC, geometric mean concentration; EBOV–GP, Ebola virus glycoprotein

†Adjusted for year of recruitment.

‡Adjusted for age at recruitment.

**Appendix Table 3.** Distribution of EBOV GP-specific binding antibody seroprevalence estimates by using different cut-offs, Sierra Leone\*

Cutoff, EU/mL	No. seropositive/no. tested (%),	
	n = 1,272	95% CI
>LLOQ (36.11)	684 (53.8)	51.0–56.5
>100	409 (32.2)	29.6–34.8
>200	274 (21.5)	19.4–23.9
>300	199 (15.6)	13.7–17.7
>400	158 (12.4)	10.7–14.4
>500	127 (10.0)	8.5–11.8
>607†	107 (8.4)	7.0–10.0

\*EU, ELISA units; LLOQ, lower limit of quantification.

†Seroprevalence cutoff used for the main analysis in this study and calculated in a previous study in persons from West Africa (8).

**Appendix Table 4.** Sociodemographic characteristics and EBOV GP-specific binding antibody seropositivity among participants, Sierra Leone\*

Characteristics	No. (%); n = 1,282	No. seropositive/no. tested (%)	OR (95% CI)	Adjusted OR (95% CI)†
<b>Age group, y</b>				
1–4	243 (19.0)	34/240 (14.2)	Referent, 1.0 (p<0.001)	1 (p<0.001)‡
5–9	170 (13.3)	61/168 (36.3)	3.5 (2.1–5.6)	3.5 (2.1–5.6)
10–19	354 (27.6)	126/353 (35.7)	3.4 (2.2–5.1)	3.4 (2.2–5.1)
20–39	390 (30.4)	145/387 (37.5)	3.6 (2.4–5.5)	3.6 (2.4–5.5)
≥40	125 (9.7)	45/124 (36.3)	3.5 (2.1–5.8)	3.4 (2.1–5.8)
<b>Sex</b>				
F	455 (35.5)	138/451 (30.6)	Referent, 1.0 (p = 0.332)	1 (p = 0.777)‡
M	827 (64.5)	273/821 (33.3)	1.1 (0.9–1.4)	1.0 (0.8–1.3)
<b>Highest education level completed</b>				
No education	362 (28.2)	82/360 (22.8)	Referent, 1.0 (p<0.001)	Referent, 1.0 (p = 0.888)
Primary, grades 1–6	378 (29.5)	135/374 (36.1)	1.9 (1.4–2.6)	0.9 (0.6–1.5)
Secondary school	480 (37.4)	170/477 (35.6)	1.9 (1.4–2.6)	0.9 (0.6–1.3)
College, university	62 (4.9)	24/61 (39.3)	2.2 (1.3–3.4)	1.0 (0.5–1.9)
<b>Socioeconomic status of household</b>				
Low	470 (36.7)	134/464 (28.9)	Referent, 1.0 (p = 0.104)	
Middle	396 (30.9)	130/394 (33.0)	1.2 (0.9–1.6)	
High	416 (32.5)	147/414 (35.5)	1.4 (1.0–1.8)	
<b>No. persons in the household, adults and children, n = 1,276</b>				
<5	274 (21.5)	83/270 (30.7)	Referent, 1.0 (p = 0.192)	
5–9	529 (41.4)	186/527 (35.3)	1.2 (0.9–1.7)	
≥10	473 (37.1)	142/469 (30.3)	1.0 (0.7–1.4)	
<b>Number of children in the household, n = 1,274</b>				
0–2	466 (36.6)	156/463 (33.7)	Referent, 1.0 (p = 0.725)	
3–5	536 (42.1)	166/530 (31.3)	0.9 (0.5–1.3)	
>5	272 (21.3)	87/271 (32.1)	0.9 (0.7–1.3)	
<b>Frequency of travel out of village or town of residence, n = 1,276</b>				
Never traveled	510 (40.0)	153/507 (30.2)	Referent, 1.0 (p = 0.252)	
Every day	19 (1.5)	10/19 (52.6)	2.6 (1.0–6.5)	
≥1×/wk	58 (4.5)	22/58 (37.9)	1.4 (0.8–2.5)	
≥1×/mo.	235 (18.4)	77/232 (33.2)	1.1 (0.8–1.6)	
<1×/mo.	454 (35.6)	148/450 (32.9)	1.1 (0.9–1.5)	

\*Seropositivity defined as >99.03 ELISA Units/mL. Alternative cutoff calculated in EBOV-naïve persons from the United Kingdom. EBOV GP-specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. EBOV-GP, Ebola virus glycoprotein; EVD, Ebola virus disease; OR, odds ratio.

†Adjusted for age and sex.

‡Age adjusted for sex. Sex adjusted for age.

**Appendix Table 5.** Potential EVD exposure in community or at work during the 2014–2016 Ebola outbreak and EBOV GP-specific binding antibody seropositivity among participants, Sierra Leone\*

Risk factors	No. (%), n = 1,282	No. seropositive/no. tested (%)	Odds ratio (95% CI)
<b>Living in a village/town with Ebola cases, n = 1,281</b>			
N	199 (15.5)	57/198 (28.8)	Referent, 1.0 (p = 0.252)
Y	1,082 (84.5)	353/1,073 (32.9)	1.2 (0.9–1.7)
<b>Knowing someone who had Ebola</b>			
No, don't know	1,044 (81.4)	331/1,036 (32.0)	Referent, 1.0 (p = 0.565)
Y	238 (18.6)	80/236 (33.9)	1.1 (0.8–1.5)
<b>No. EVD cases known by participant</b>			
0	1,044 (81.4)	331/1,036 (31.9)	Referent, 1.0 (p = 0.608)
1	125 (9.8)	39/125 (31.2)	1.0 (0.6–1.4)
2–3	66 (5.2)	26/65 (40.0)	1.4 (0.9–2.4)
>3	47 (3.7)	15/46 (32.6)	1.0 (0.5–1.9)
<b>Closest relationship with an EVD case, n = 1,280</b>			
No relationship†	1,044 (81.5)	331/1,036 (32.0)	Referent, 1.0 (p = 0.500)
Close family‡	27 (2.1)	7/27 (25.9)	0.7 (0.3–1.8)
Other relative	52 (4.1)	16/51 (31.4)	1.0 (0.5–1.8)
Friend	59 (4.6)	18/59 (30.5)	0.9 (0.5–1.7)
Community member	98 (7.7)	39/97 (40.2)	1.4 (0.9–2.2)
<b>Living in the same household with an EVD case, n = 1,280</b>			
N	1,269 (99.1)	407/1,260 (32.3)	Referent, 1.0 (p = 0.876)
Y	11 (0.9)	3/10 (30.0)	0.9 (0.2–3.5)
<b>Caring for an EVD case, n = 1,281</b>			
N	1,272 (99.3)	408/1,262 (32.3)	Referent, 1.0 (p = 0.504)



Risk factors	No. (%), n = 1,282	No. seropositive/no. tested (%)	Odds ratio (95% CI)
Y	9 (0.7)	2/9 (22.2)	0.6 (0.1–2.9)
Direct body contact with an EVD case, n = 1,281			
N	1,275 (99.5)	408/1,265 (32.3)	Referent, 1.0 (p = 0.955)
Y	6 (0.5)	2/6 (33.3)	1.1 (0.2–5.8)
Attending a funeral of an EVD case			
N	1,263 (98.5)	404/1,254 (32.2)	Referent, 1.0 (p = 0.554)
Y	19 (1.5)	7/18 (38.9)	1.3 (0.5–3.5)
Health care frontline worker during EVD outbreak			
No, NA§	1,254 (97.8)	403/1,244 (32.4)	Referent, 1.0 (p = 0.665)
Y	28 (2.2)	8/28 (28.6)	0.8 (0.4–1.9)

\*Seropositivity defined as >99.03 ELISA units/mL. Alternative cutoff calculated in EBOV-naive persons from the United Kingdom. EBOV GP-specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. Because none of the variables was associated with seropositivity in univariable analysis, the adjusted odds ratio column is omitted from the table. EBOV GP, Ebola virus glycoprotein; EVD, Ebola virus disease; NA, not applicable.

†No relationship; participant did not know anyone with Ebola.

‡Participant was the parent or child or spouse or sibling of an EVD case.

§Not applicable; participant was a child or did not have a job.

**Appendix Table 6.** Potential risk factors for transmission of Ebola virus from animals during the 2014–2016 Ebola outbreak and EBOV GP-specific binding antibody seropositivity among participants, Sierra Leone\*

Risk Factors	No. (%), n = 1,282	No. seropositive/no. tested (%)	OR (95% CI)	Adjusted OR (95% CI)†
Number of domestic animals in the participant's compound				
0	503 (39.2)	150/498 (30.1)	Referent, 1.0 (p = 0.362)	
1–5	374 (29.2)	122/371 (32.8)	1.1 (0.9–1.5)	
>5	405 (31.6)	139/403 (34.5)	1.2 (0.9–1.6)	
Having the following domestic animals in the compound, n = 1,281‡				
Dog				
N	1,116 (87.1)	353/1,107 (31.9)	Referent, 1.0 (p = 0.377)	
Y	165 (12.9)	58/164 (35.4)	1.2 (0.8–1.6)	
Cat				
N	951 (74.2)	304/943 (32.2)	Referent, 1.0 (p = 0.898)	
Y	330 (25.8)	107/328 (32.6)	1.0 (0.8–1.3)	
Goat, sheep				
N	870 (67.9)	277/863 (32.1)	Referent, 1.0 (p = 0.790)	
Y	411 (32.1)	134/408 (32.8)	1.0 (0.8–1.3)	
Pig				
N	1,263 (98.6)	399/1,253 (31.8)	Referent, 1.0 (p = 0.003)	Referent, 1.0 (p = 0.004)
Y	18 (1.4)	12/18 (66.7)	4.3 (1.6–11.5)	4.1 (1.5–11.4)
Other				
N	825 (64.4)	258/817 (31.6)	Referent, 1.0 (p = 0.439)	
Y	456 (35.6)	153/454 (33.7)	1.1 (0.9–1.4)	
Touching sick or dead domestic animals				
N	1,253 (97.7)	400/1,243 (32.2)	Referent, 1.0 (p = 0.518)	
Y	29 (2.3)	11/29 (37.9)	1.3 (0.6–2.8)	
Hunting for wild animals§				
N	1,261 (99.3)	404/1,251 (32.3)	Referent, 1.0 (p = 0.947)	
Y	9 (0.7)	3/9 (33.3)	1.0 (0.3–4.2)	
Touching sick or dead wild animals				
N	1,277 (99.6)	410/1,267 (32.4)	Referent, 1.0 (p = 0.538)	
Y	5 (0.4)	1/5 (20.0)	0.5 (0.1–4.7)	
Consumption of bush meat				
N	1,275 (99.4)	409/1,265 (32.3)	Referent, 1.0 (p = 0.830)	
Y	7 (0.6)	2/7 (28.6)	0.8 (0.2–4.3)	

\*Seropositivity defined as >99.03 ELISA units/mL. Alternative cutoff calculated in EBOV-naive persons from the United Kingdom. EBOV GP-specific binding antibodies were indeterminate in 10 participants. p values calculated by using likelihood ratio test. EBOV-GP, Ebola virus glycoprotein.

†Adjusted for age and sex.

‡Participants could indicate >1 type of domestic animal.

§Types of wild animals hunted by participants who answered yes included monkeys, duiker antelopes, bats, and rodents.

**Appendix Table 7.** Additional sociodemographic characteristics of the study population not included in the risk factor analysis of Ebola virus IgG seroprevalence, Sierra Leone

Characteristics	No. (%); n = 1,282
Occupation	
Salaried employment	74 (5.8)
Self-employed, e.g., trader or farmer	211 (16.5)
Housewife	18 (1.4)
Unemployed	78 (6.1)
Student or apprentice	635 (49.5)
Preschool child	259 (20.2)
Other	7 (0.5)
Religion*	
Muslim	1,062 (82.9)
Christian	217 (16.9)
None	2 (0.2)
Tribe	
Themne	861 (67.2)
Limba	159 (12.4)
Soso	115 (9.0)
Fula	36 (2.8)
Mende	44 (3.4)
Other	67 (5.2)

\*Religion not available for 1 participant.

**Appendix Table 8.** Additional travel information for persons reporting travel outside their village or city of residence during the Ebola virus disease outbreak, Sierra Leone, March 2014–January 2016

Characteristics	No. (%); n = 770*
Destination of most recent journey†	
Major cities, i.e., Freetown	361 (46.9)
Village in the same chiefdom	172 (22.3)
Different chiefdom within same district	136 (17.7)
Another district within Sierra Leone	43 (5.6)
Guinea	49 (6.4)
Traveling time to the farthest destination‡	
<1 h	148 (19.4)
1–2 h	251 (32.9)
3–6 h	344 (45.2)
All day, >1 d	19 (2.5)
Purpose of the trip	
Visiting someone	498 (64.7)
Work, business	141 (18.3)
Attending a funeral	22 (2.8)
Attending another event§	36 (4.7)
Seeking healthcare	9 (1.2)
Accompanying somebody	13 (1.7)
Study or holiday	16 (2.1)
Other reasons	35 (4.5)

\*N = 770 correspond to 766 participants who reported a travel frequency in Appendix Table 1 plus 4 participants with missing data on travel frequency but who reported a travel destination for their most recent journey outside their village/town of residence.

†Participants could indicate more than one destination; information not available for 40 participants.

‡Information not available for 8 participants.

§Other events included weddings, feasts, football matches, and religious ceremonies.

**Appendix Table 9.** Information on illness or medical issues during the Ebola virus disease outbreak, Sierra Leone, March 2014–January 2016\*

Characteristics	No. (%) <sup>†</sup> ; n = 1,282
Being unwell during the EVD outbreak	
Y	219 (17.1)
N	1,051 (82.0)
Don't know, don't remember	11 (0.9)
Participants who reported being unwell during the EVD outbreak, n = 219 <sup>†</sup>	
Medical issues or symptoms	
Headache	169 (77.2)
Fever	111 (50.7)
Vomiting	25 (11.4)
Diarrhea	18 (8.2)
Joint and muscle pain	73 (33.3)
Rash	17 (7.8)
Muscle weakness	39 (17.8)
Other symptoms	30 (13.7)
Duration of symptoms	
Few hours	51 (23.3)
1–2 d	96 (43.8)
About 1 week	47 (21.5)
>1 week	22 (10.0)
Don't know	3 (1.4)
Seen by a doctor or nurse, n = 216	
Y	97 (44.9)
N	119 (55.1)
Any condition diagnosed, n = 216	
Y <sup>‡</sup>	80 (37.0)
N	11 (5.1)
Don't know, don't remember	6 (2.8)
Not applicable <sup>§</sup>	119 (55.1)
Given any treatment, n = 216	
Y	94 (43.5)
N	2 (0.9)
Don't know, don't remember	1 (0.5)
Not applicable <sup>§</sup>	119 (55.1)
Female participants of childbearing potential, aged 16–50 y, n = 157	
Experienced a miscarriage during the EVD outbreak	
Y	2 (1.6)
N	125 (98.4)
Experienced a stillbirth during the EVD outbreak	
Y	1 (0.8)
N	126 (99.2)

\*EVD, Ebola virus disease.

<sup>†</sup>Percentages calculated only among the participant who reported being unwell during the EVD outbreak, n = 219.

Information not available in 3 participants.

<sup>‡</sup>Diagnoses: malaria (n = 45); typhoid fever/diarrhea with or without concomitant malaria infection (n = 9); pneumonia (n = 1); pulmonary tuberculosis (n = 1); other conditions (n = 14); no diagnosis available (n = 14).

<sup>§</sup>Not applicable participants were not seen by a doctor.